As the pathogenesis of LAM is being further clarified, other therapeutic agents such as VEGFD inhibitors, statins, chloroquine analogs, cyclin‐dependent kinase inhibitors, matrix metalloproteinase inhibitors, and their combinations also are used in LAM. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.